Apellis Pharmaceuticals, Inc.

Ticker

APLS

ISIN

US03753U106

Price

USD 47.71

Change Today

+0.22 / 0.463 %

Price 1 year ago

82.92 / -42.463 %

Market Capitalization

4,809,480,704.00

52 Week Low

23.65

52 Week High

93.31

200 Day Moving Average

51.00

50-day Moving Average

55.90


Price evolution

Yearly Returns


Peers


Peers

Company information

Summary

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Country

United States

Exchange

NMS

Earnings Per Share

-4.7

P/E Ratio

-

Debt/Equity Ratio

45.522

Beta

1.498625

City

Waltham

Address

100 Fifth Avenue

Zip

02451

Ebitda

-539,209,984.00

-

Enterprise to Ebitda

-9.72

Enterprise Value

5,240,167,936.00

Target Price

73.19

Estimated Price

-

Book Value

0.64

Expected Growth

-

Balance sheet

Income statement

Sustainability

Correlation

Company Name Correlation
DNA Ginkgo Bioworks Holdings, Inc. -0.73
300122.SZ CHONGQING ZHIFEI B -0.58
300363.SZ PORTON PHARMA SOLU -0.54
BLUE bluebird bio, Inc. -0.51
ATHX Athersys, Inc. -0.49
TMBR Timber Pharmaceuticals, Inc. -0.48
300497.SZ JIANGXI FUSHINE PH -0.47
002007.SZ HUALAN BIOLOGICAL -0.39
300147.SZ XIANGXUE PHARMACEU -0.39
1177.HK SINO BIOPHARM -0.34
600201.SS JINYU BIO-TECHNOLOGY CO LTD -0.32
1801.HK INNOVENT BIO -0.29
2269.HK WUXI BIO -0.20
1530.HK 3SBIO -0.20
AKBA Akebia Therapeutics, Inc. -0.17
002252.SZ S/H RAAS BLOOD PRO -0.11
0775.HK CKLIFE SCIENCES -0.09
1873.HK VIVA BIOTECH -0.03
TRX.L TISSUE REGENIX GROUP PLC 0.03
2370.T MEDINET CO LTD 0.05
ALPHA.PA PHARNEXT 0.05
300204.SZ STAIDSON (BEIJING) 0.10
300009.SZ ANHUI ANKE BIOTECH 0.11
2137.HK BRII-B 0.21
600200.SS JIANGSU WUZHONG PHARMACEUTICAL 0.36
IMU.AX IMUGENE FPO 0.41
300181.SZ ZHEJIANG JOLLY PHA 0.57
600866.SS STAR LAKE BIOSCIENCE CO INC Z 0.59

Similar companies

Ticker Name City Country Currency Exchange Beta EV/EBITDA Employees Site
ALPHA.PA PHARNEXT Issy-les-Moulineaux France EUR PAR 2.86 -0.65 40 https://www.pharnext.com
1177.HK SINO BIOPHARM Wan Chai Hong Kong HKD HKG 0.48 17.58 25579 https://www.sinobiopharm.com
0775.HK CKLIFE SCIENCES Tai Po Hong Kong HKD HKG 0.40 32.46 1855 https://www.ck-lifesciences.com
DNA Ginkgo Bioworks Holdings, Inc. Boston United States USD NYQ -1.24 641 https://www.ginkgobioworks.com
002252.SZ S/H RAAS BLOOD PRO Shanghai China CNY SHZ 0.21 19.62 2966 https://www.raas-corp.com
002007.SZ HUALAN BIOLOGICAL Xinxiang China CNY SHZ 0.03 19.25 2927 https://www.hualanbio.com
600200.SS JIANGSU WUZHONG PHARMACEUTICAL Suzhou China CNY SHH 0.56 -710.43 https://www.600200.com
600866.SS STAR LAKE BIOSCIENCE CO INC Z Zhaoqing China CNY SHH 0.35 21.35 2608 https://www.starlake.com.cn
TRX.L TISSUE REGENIX GROUP PLC Garforth United Kingdom GBp LSE 1.40 -10.94 79 https://www.tissueregenix.com
2269.HK WUXI BIO Wuxi China HKD HKG 0.91 85.17 9864 https://www.wuxibiologics.com
IMU.AX IMUGENE FPO Sydney Australia AUD ASX 2.28 -30.30 https://www.imugene.com
600201.SS JINYU BIO-TECHNOLOGY CO LTD Hohhot China CNY SHH 0.31 18.76 1580 https://www.jinyu.com.cn
TMBR Timber Pharmaceuticals, Inc. Basking Ridge United States USD ASE 0.19 5 https://www.timberpharma.com
300181.SZ ZHEJIANG JOLLY PHA Huzhou China CNY SHZ 0.10 18.50 2132 https://www.zuoli.com
CLVS Clovis Oncology, Inc. Boulder United States USD NMS 0.49 -3.78 413 https://www.clovisoncology.com
ATHX Athersys, Inc. Cleveland United States USD NCM -1.30 -0.60 104 https://www.athersys.com
VTGN VistaGen Therapeutics, Inc. South San Francisco United States USD NCM 1.06 0.75 36 https://www.vistagen.com
300009.SZ ANHUI ANKE BIOTECH Hefei China CNY SHZ 0.38 19.32 https://www.ankebio.com
300122.SZ CHONGQING ZHIFEI B Chongqing China CNY SHZ 0.77 11.89 4800 https://www.zhifeishengwu.com
2370.T MEDINET CO LTD Tokyo Japan JPY JPX 1.34 -2.69 92 https://www.medinet-inc.co.jp
2137.HK BRII-B Beijing China HKD HKG -5.41 113 https://www.briibio.com
1530.HK 3SBIO Shenyang China HKD HKG 0.84 6.75 5292 https://www.3sbio.com
1801.HK INNOVENT BIO Suzhou China HKD HKG -0.31 -14.04 5568 https://www.innoventbio.com
300497.SZ JIANGXI FUSHINE PH Jingdezhen China CNY SHZ 0.14 35.19 1849 https://www.fushine.cn
300147.SZ XIANGXUE PHARMACEU Guangzhou China CNY SHZ 0.59 374.63 3378 https://www.xphcn.com
BLUE bluebird bio, Inc. Cambridge United States USD NMS 1.38 -0.35 518 https://www.bluebirdbio.com
300204.SZ STAIDSON (BEIJING) Beijing China CNY SHZ 0.16 -27.06 873 https://www.staidson.com
AKBA Akebia Therapeutics, Inc. Cambridge United States USD NGM 1.47 -0.16 426 https://www.akebia.com
1873.HK VIVA BIOTECH Shanghai China HKD HKG 0.95 15.94 2127 https://www.vivabiotech.com.cn
300363.SZ PORTON PHARMA SOLU Chongqing China CNY SHZ -0.36 30.90 4158 https://www.porton.cn
VLON Vallon Pharmaceuticals Inc. Philadelphia United States USD NCM -1.15 -0.24 2 https://www.vallon-pharma.com
SRNE Sorrento Therapeutics, Inc. San Diego United States USD NCM 2.17 -2.59 799 https://www.sorrentotherapeutics.com
NVAX Novavax, Inc. Gaithersburg United States USD NMS 1.58 -2.58 1541 https://www.novavax.com
300759.SZ PHARMARON BEIJING Beijing China CNY SHZ 0.28 49.23 14923 https://www.pharmaron.com
300404.SZ BOJI MEDICAL & TEC Guangzhou China CNY SHZ -0.10 63.41 989 https://www.bojicro.com
RIGL Rigel Pharmaceuticals, Inc. South San Francisco United States USD NMS 1.66 -2.33 165 https://www.rigel.com
688180.SS SHANGHAI JUNSHI BIOSCIENCES CO Shanghai China CNY SHH 0.24 -39.92 2805 https://www.junshipharma.com
600161.SS BEIJING TIANTAN BIOLOGICAL PROD Beijing China CNY SHH 0.02 23.29 3933 https://www.tiantanbio.com
9939.HK KINTOR PHARMA-B Suzhou China HKD HKG -0.77 -5.99 316 https://www.kintor.com.cn
VERU Veru Inc. Miami United States USD NCM -0.41 -41.18 252 https://www.verupharma.com

Funds


Mutual Fund Holders

Social

Dividends

Ratings

News

Earnings

SEC Filings

Options

Indicators

Glossary
Momentum
A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
Inertia
In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
Relative Strength Index (RSI)
A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
Fibonacci's Weighted Moving Average
A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
Williams %R
A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
Relative Volatility Index (RVI)
A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
Commodity Channel Index (CCI)
A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.